Theranostics 2019; 9(16):4717-4729. doi:10.7150/thno.33680 This issue Cite

Research Paper

CDYL promotes the chemoresistance of small cell lung cancer by regulating H3K27 trimethylation at the CDKN1C promoter

Zhengang Qiu1,3#, Weiliang Zhu1#, Hui Meng1#, Lihua Tong1,4#, Xi Li1, Peng Luo1, Lilan Yi1, Xiaoli Zhang1, Linlang Guo2✉, Ting Wei1✉, Jian Zhang1✉

1. Department of Oncology, Zhujiang Hospital, Southern Medical University, Guangzhou 510282, Guangdong, China
2. Department of Pathology, Zhujiang Hospital, Southern Medical University, Guangzhou 510282, Guangdong, China
3. Department of Oncology, First Affiliated Hospital of Gannan Medical University, Ganzhou 341000, Jiangxi, China
4. Department of Oncology, Nanhai Hospital Affiliated to Southern Medical University, Foshan 528200, Guangdong, China
# These authors contributed equally to this study

Citation:
Qiu Z, Zhu W, Meng H, Tong L, Li X, Luo P, Yi L, Zhang X, Guo L, Wei T, Zhang J. CDYL promotes the chemoresistance of small cell lung cancer by regulating H3K27 trimethylation at the CDKN1C promoter. Theranostics 2019; 9(16):4717-4729. doi:10.7150/thno.33680. https://www.thno.org/v09p4717.htm
Other styles

File import instruction

Abstract

Graphic abstract

Rationale: Chemoresistance frequently occurs in patients with small cell lung cancer (SCLC) and leads to a dismal prognosis. However, the mechanisms underlying this process remain largely unclear.

Methods: The effects of chromodomain Y-like (CDYL) on chemoresistance in SCLC were determined using Western blotting, immunohistochemistry, cell counting kit-8 assays, flow cytometry, and tumorigenicity experiments, and the underlying mechanisms were investigated using mRNA sequencing, chromatin immunoprecipitation-qPCR, electrophoretic mobility shift assays, co-immunoprecipitation, GST pull down assays, bisulfite sequencing PCR, ELISA, and bioinformatics analyses.

Results: CDYL is expressed at high levels in chemoresistant SCLC tissues from patients, and elevated CDYL levels correlate with an advanced clinical stage and a poor prognosis. Furthermore, CDYL expression is significantly upregulated in chemoresistant SCLC cells. Using gain- and loss-of-function methods, we show that CDYL promotes chemoresistance in SCLC in vitro and in vivo. Mechanistically, CDYL promotes SCLC chemoresistance by silencing its downstream mediator cyclin-dependent kinase inhibitor 1C (CDKN1C). Further mechanistic investigations showed that CDYL recruits the enhancer of zeste homolog 2 (EZH2) to regulate trimethylation of lysine 27 in histone 3 (H3K27me3) at the CDKN1C promoter region and promotes transcriptional silencing. Accordingly, the EZH2 inhibitor GSK126 de-represses CDKN1C and decreases CDYL-induced chemoresistance in SCLC.

Principal conclusions: Based on these results, the CDYL/EZH2/CDKN1C axis promotes chemoresistance in SCLC, and these markers represent promising therapeutic targets for overcoming chemoresistance in patients with SCLC.

Keywords: small cell lung cancer, chemoresistance, CDYL, CDKN1C, H3K27me3


Citation styles

APA
Qiu, Z., Zhu, W., Meng, H., Tong, L., Li, X., Luo, P., Yi, L., Zhang, X., Guo, L., Wei, T., Zhang, J. (2019). CDYL promotes the chemoresistance of small cell lung cancer by regulating H3K27 trimethylation at the CDKN1C promoter. Theranostics, 9(16), 4717-4729. https://doi.org/10.7150/thno.33680.

ACS
Qiu, Z.; Zhu, W.; Meng, H.; Tong, L.; Li, X.; Luo, P.; Yi, L.; Zhang, X.; Guo, L.; Wei, T.; Zhang, J. CDYL promotes the chemoresistance of small cell lung cancer by regulating H3K27 trimethylation at the CDKN1C promoter. Theranostics 2019, 9 (16), 4717-4729. DOI: 10.7150/thno.33680.

NLM
Qiu Z, Zhu W, Meng H, Tong L, Li X, Luo P, Yi L, Zhang X, Guo L, Wei T, Zhang J. CDYL promotes the chemoresistance of small cell lung cancer by regulating H3K27 trimethylation at the CDKN1C promoter. Theranostics 2019; 9(16):4717-4729. doi:10.7150/thno.33680. https://www.thno.org/v09p4717.htm

CSE
Qiu Z, Zhu W, Meng H, Tong L, Li X, Luo P, Yi L, Zhang X, Guo L, Wei T, Zhang J. 2019. CDYL promotes the chemoresistance of small cell lung cancer by regulating H3K27 trimethylation at the CDKN1C promoter. Theranostics. 9(16):4717-4729.

This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.
Popup Image